eligibility_summary
Adults 18–75 with CD19+ DLBCL/TFL/PMBCL/MCL or transformed indolent B‑NHL, R/R (DLBCL ≥2L or ≤12 mo post‑ASCT, MCL after/intolerant to BTKi, indolent ≥3L). Prior CD20 mAb/anthracycline, ≥1 measurable lesion, ECOG 0–2, adequate organ function. Transplant/CAR‑T allowed, washout ≥3 wks. Exclude: allergy, other cancer, GVHD ≥II, recent gene therapy, active infection, HBV/HCV/HIV/syphilis (low HBV DNA may be OK), NYHA III–IV, unresolved >G1 tox, CNS disease/lymphoma, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 1) Cord blood–derived CD19 CAR‑NK (living cell therapy, allogeneic NK cells engineered with an anti‑CD19 CAR). Mechanism: CAR recognition of CD19 on malignant B cells triggers NK cytotoxicity (perforin/granzyme) with low GVHD/CRS risk. 2) 7×19 CAR‑T (living cell therapy, gene‑modified T cells bearing a CD19 CAR and armored to express IL‑7 and CCL19 to enhance proliferation, survival, and trafficking/recruitment of T cells and dendritic cells). Dosing: CAR‑NK 2×10^6/kg on Day 0, then 7×19 CAR‑T 2×10^6/kg on Day 7. Targets/pathways: CD19+ B‑cell lymphomas (DLBCL, PMBCL, MCL, TFL), activation of cytotoxic lymphocyte pathways, IL‑7/CCL19 chemokine signaling to improve tumor infiltration and immune engagement. Purpose: evaluate safety/efficacy of sequential CD19 CAR‑NK then 7×19 CAR‑T in R/R B‑cell lymphoma.